Advertisement
Singapore markets closed
  • Straits Times Index

    3,280.10
    -7.65 (-0.23%)
     
  • Nikkei

    37,934.76
    +306.28 (+0.81%)
     
  • Hang Seng

    17,651.15
    +366.61 (+2.12%)
     
  • FTSE 100

    8,139.83
    +60.97 (+0.75%)
     
  • Bitcoin USD

    63,984.41
    -773.78 (-1.19%)
     
  • CMC Crypto 200

    1,331.87
    -64.66 (-4.63%)
     
  • S&P 500

    5,106.45
    +58.03 (+1.15%)
     
  • Dow

    38,288.59
    +202.79 (+0.53%)
     
  • Nasdaq

    15,932.76
    +321.00 (+2.06%)
     
  • Gold

    2,350.40
    +7.90 (+0.34%)
     
  • Crude Oil

    83.90
    +0.33 (+0.39%)
     
  • 10-Yr Bond

    4.6730
    -0.0330 (-0.70%)
     
  • FTSE Bursa Malaysia

    1,575.16
    +5.91 (+0.38%)
     
  • Jakarta Composite Index

    7,036.08
    -119.22 (-1.67%)
     
  • PSE Index

    6,628.75
    +53.87 (+0.82%)
     

Analyzing Axovant Sciences’ Valuation Metrics

Analyzing Axovant Sciences’ Valuation Metrics

In September, there are seven analysts covering Axovant Sciences (AXON) stock. Two of them have given the stock a “buy” rating, and five have given it a “hold.” The mean rating for Axovant stock is 2.71 with a target price of $4.70, implying an upside potential of 129.3% over its trading price of $2.05 on September 11.